Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics
02 Julio 2024 - 9:00AM
Business Wire
Rondo Therapeutics, a privately-held biopharmaceutical company
advancing next-generation immuno-oncology platforms, announces the
appointment of Steven James to its Board of Directors. Mr. James
brings over three decades of biopharmaceutical experience to
Rondo’s Board of Directors. He was instrumental in building and
leading several companies into the clinic, resulting in $2B+ in
M&A value for stakeholders. Mr. James’ addition to the Board of
Directors strengthens Rondo’s leadership team as the company
continues to drive development of T-cell engaging bispecific
antibodies for solid tumors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240702603290/en/
Steven James - Biotech CEO and
Independent Board Member (Photo: Business Wire)
“We are thrilled to welcome Steve to the Board,” said Shelley
Force Aldred, co-founder, and CEO of Rondo Therapeutics. “With
Steve’s business acumen and transactional experience, our board and
leadership team are uniquely positioned to deliver transformative
solid tumor therapies to patients.”
“There is great therapeutic potential for bispecific antibodies
to address significant unmet needs in solid tumors. I am impressed
by what the team at Rondo Therapeutics has accomplished to date,
and I am excited to be a part of Rondo’s continued growth,” said
Mr. James.
Mr. James comes to Rondo with a proven record of building
companies in the biotech industry. Most recently he was President
and CEO of Pionyr Immunotherapeutics. Under his leadership the
company made significant therapeutic advances in novel target
discovery and antibody generation, targeting immunosuppressive
cells in the tumor microenvironment. The company was acquired in
parts by Gilead and Ikena Oncology. Prior to Pionyr, Mr. James
served as president and CEO of Labrys Biologics, leading its
acquisition by Teva Pharmaceuticals. Before Labrys, Mr. James was
president and CEO of KAI Pharmaceuticals which was acquired by
Amgen. Mr. James also serves on the boards of Juneva Therapeutics,
Lyterian Therapeutics, Ventus Therapeutics, and Allakos, Inc.
Mr. James has held leadership positions at Exelixis, Sunesis
Pharmaceuticals, Ionis Pharmaceuticals, and Eli Lilly. He received
his MBA from Kellogg School of Northwestern University and an
undergraduate degree in neuroscience from Brown University.
About Rondo Therapeutics:
Rondo Therapeutics is a biopharmaceutical company exploring new
frontiers in cancer therapy. Rondo Therapeutics’ mission is to
advance bispecific antibody therapies, specifically targeting unmet
needs in solid tumors. Our solution is to create a new class of
bispecific antibodies that harness the immune system’s power to
target and eliminate tumors safely. For more information, please
visit www.rondotx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702603290/en/
Rondo Therapeutics Meghana Rao, VP of Business Development
meghana@rondotx.com